- 著者
-
Ryu Shutta
Daisaku Nakatani
Yasuhiko Sakata
Shungo Hikoso
Hiroya Mizuno
Shinichiro Suna
Tetsuhisa Kitamura
Katsuki Okada
Tomoharu Dohi
Takayuki Kojima
Bolrathanak Oeun
Akihiro Sunaga
Hirota Kida
Hiroshi Sato
Masatsugu Hori
Issei Komuro
Masami Nishino
Yasushi Sakata
on behalf of the Osaka Acute Coronary Insufficiency Study (OACIS) Investigators
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Reports (ISSN:24340790)
- 巻号頁・発行日
- vol.2, no.5, pp.280-287, 2020-05-08 (Released:2020-05-08)
- 参考文献数
- 25
- 被引用文献数
-
1
Background:Studies comparing the cardiac consequences of hydrophilic and lipophilic statins in experimental and clinical practice settings have produced inconsistent results. In particular, evidence focusing on diabetic patients after acute myocardial infarction (AMI) is lacking.Methods and Results:From the Osaka Acute Coronary Insufficiency Study (OACIS) registry database, 1,752 diabetic patients with AMI who were discharged with a prescription for statins were studied. Long-term outcomes were compared between hydrophilic and lipophilic statins, including all-cause death, recurrent myocardial infarction (re-MI) and admission for heart failure (HF) and a composite of these (major adverse cardiac events; MACE). During a median follow-up period of 1,059 days, all-cause death, non-fatal re-MI, admission for HF, and MACE occurred in 95, 89, 112 and 249 patients, respectively. Although there was no significant difference between statins in the risk of all-cause death, re-MI and MACE, the risk of HF admission was significantly lower in patients with hydrophilic than lipophilic statins before (adjusted hazard ratio [aHR], 0.560; 95% CI: 0.345–0.911, P=0.019) and after (aHR, 0.584; 95% CI: 0.389–0.876, P=0.009) propensity score matching. Hydrophilic statin use was consistently associated with lower risk for HF admission than lipophilic statins across the subgroup categories.Conclusions:In the present diabetic patients with AMI, hydrophilic statins were associated with a lower risk of admission for HF than lipophilic statins.